175 results
Page 4 of 9
8-K
EX-99.2
aewr7v mt
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
eroid7usczz awxs8bkb
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
sjf7s4qa9o9
16 Mar 21
Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates
7:15am
8-K
EX-99.1
a915beq
8 Mar 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
7:05am
8-K
ccmc2z gt64
8 Mar 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
7:05am
8-K
EX-99.1
02xod
2 Mar 21
Regulation FD Disclosure
8:00am
424B5
h3v 9w546g7dn9
16 Feb 21
Prospectus supplement for primary offering
7:05am
8-K
EX-10.1
mbr3n78ahtpi
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
EX-99.1
7fn39exlv075 2v5zkth
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
EX-99.1
iti9mv6p5vny712zpb
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.2
3wepu depz
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-10.1
o2q6pslf
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
8-K
EX-99.1
uq87mbte i46vc98ybtw
5 Nov 20
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
4:31pm
8-K
EX-99.1
liduk7wgutx xtyctsed
8 Oct 20
Regulation FD Disclosure
5:01pm
8-K
EX-99.1
4zv36b4m vkcn
3 Aug 20
Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
4:10pm